Bayer AG

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

A Missouri jury found in favor of plaintiffs as verdicts seesaw in trials involving the fertilizer.

Bayer Told to Pay $1.56 Billion After Losing Roundup Case

Bayer said on Friday it was voluntarily recalling one lot of its cancer drug Vitrakvi due to the presence of microbial contamination.

Bayer recalls one lot of cancer drug Vitrakvi

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer is voluntarily recalling one lot of Vitrakvi® (larotrectinib) Oral Solution 20 mg/mL in 100mL glass bottles to the consumer/user level. The product is being recalled due to microbial contamination identified as Penicillium brevicompactum observed during routine ongoing stability testing. Risk Statement: Given that Vitrakvi® is indicated for the treatment of solid tumors that are NTRK gene fusion positive, it is expected that patients on Vitrakvi® may be im.

Bayer Issues Voluntary Recall Nationwide of VITRAKVI® (larotrectinib) Oral Solution 20 mg/mL Due to Presence of Microbial Contamination

Bayer on Monday said it would voluntarily withdraw the follicular lymphoma drug Aliqopa, also known as copanlisib, from the U.S. market after a trial designed to confirm its benefit did not show the desired effect on overall survival.

Bayer withdraws follicular lymphoma drug after further trial fails

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that, following discussions with the U.S. Food and Drug Administration (FDA), it will work with the FDA on a voluntary withdrawal of the Aliqopa® (copanlisib) U.S. New Drug Application for adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies. Aliqopa® was granted accelerated approval by the FDA in September 2017 based on CHRONOS-1, an open-label, single-arm Phase II study. The FDA req.

Bayer Provides Update on Aliqopa® (copanlisib)

Bayer said on Friday that the European Medicines Agency recommended approval of a higher dose version of eye drug Eylea for treatment of a leading cause of blindness among the elderly, stepping up competition with Roche.

European regulator endorses high-dose version of Bayer eye drug Eylea

CNH Industrial NV

Lloyds Banking Group

A long-awaited bounce for Old World shares relative to the U.S. hasn't happened yet. But consider these cash-flow favorites from Oakmark International manager David Herro just the same.

3 Stock Bargains From Europe. Yes, Europe.

Recursion Pharmaceuticals

BERLIN & SALT LAKE CITY--(BUSINESS WIRE)--Bayer and US-based Recursion Pharmaceuticals, Inc., a clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that they have updated the focus of their research collaboration to precision oncology. The oncology-focused collaboration will leverage Bayer's small molecule compound library and expertise in biology and medicinal chemistry as well as Recursion's purpose-built artificial intelligence-guided drug discove.

Bayer and Recursion focus research collaboration on Oncology

Bayer (BAYRY) reports weaker-than-expected third-quarter 2023 results. Management maintains its 2023 outlook.

Bayer's (BAYRY) Q3 Earnings and Revenues Miss Estimates

Bayer Aktiengesellschaft (OTCPK:BAYZF) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants Jost Reinhard - Senior Vice President & Head-Investor Relations Bill Anderson - Chief Executive Officer Wolfgang Nickl - Chief Financial Officer Rodrigo Santos - President, Crop Science Division Stefan Oelrich - President, Pharmaceuticals Division Heiko Schipper - President, Consumer Health Division Conference Call Participants Peter Verdult - Citi Sachin Jain - Bank of America Vincent Andrews - Morgan Stanley Emily Field - Barclays Joel Jackson - BMO Capital Markets Florent Cespedes - Société Générale Christian Faitz - Kepler Cheuvreux Laurent Favre - BNP Steve Byrne - Bank of America Falko Friedrichs - Deutsche Bank James Quigley - Morgan Stanley Operator Ladies and gentlemen, thank you for standing by. Welcome to Bayer's Investor and Analyst Conference Call on the Third Quarter 2023 results.

Bayer Aktiengesellschaft (BAYZF) Q3 2023 Earnings Call Transcript

Bayer's new CEO Bill Anderson on Wednesday vowed to “remove multiple layers of management” within the German pharmaceutical giant by the end of 2024 as he outlined plans to split the firm up after declaring that its performance is “not acceptable.”.

Bayer vows to cut ‘multiple layers of management' by end of 2024 as new CEO says firm's performance is ‘not acceptable'

Mercedes-Benz Group AG

German stocks are not doing well as the economy goes through substantial challenges. The most recent data showed that business confidence has tumbled while manufacturing and services PMIs have remained below 50.

These 5 DAX index companies are in trouble as their stocks plunge

BERLIN & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bayer and the Broad Institute of MIT and Harvard today announced that they have extended their research collaboration of 10 years by an additional five years, to develop and advance innovative cancer treatments. The expanded agreement will focus on joint cancer target identification and discovery of new therapeutic approaches in oncology. “We are constantly working to discover novel ways to treat this devastating disease affecting millions of people w.

Bayer and Broad Institute of MIT and Harvard Extend Research Collaboration to Develop New Cancer Therapies

A California jury found Bayer liable in a case brought by a man who claimed his cancer was due to exposure to the company's Roundup weed killer, and ordered it to pay $332 million in damages, Law.com reported on Tuesday.

Bayer ordered to pay $332 mln in Roundup cancer trial -Law.com

Bayer's stock is undervalued and offers potential for long-term recovery. Revenues have been quite strong for a while. But earnings have not shown sustainable growth. Key growth stimuli include resolving glyphosate issues and new drugs, but risks include litigation and debt.

Bayer Stock: Good Value For Money

IRVING, Texas--(BUSINESS WIRE)-- #AdvancedManufacturing--Fluor Completes Bayer's First Global Cell Therapy Launch Facility in Berkeley, California.

Fluor Completes Bayer's First Global Cell Therapy Launch Facility in Berkeley, California

MENLO PARK, Calif.--(BUSINESS WIRE)--HALO Precision Diagnostics (“HALO”), a leader in early disease detection using precision diagnostics, today announced a collaboration with Bayer, a global leader in radiology, to join QUANTI, Bayer's Phase III clinical development program for gadoquatrane. Bayer initiated the QUANTI studies to evaluate the safety and efficacy of gadoquatrane, an investigational gadolinium-based contrast agent, in MRI. Contrast-enhanced MRI plays a key role in the healthcare.

HALO Precision Diagnostics Collaborating with Bayer to Advance Contrast-Enhanced MRI

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will present new data from across its oncology portfolio at the upcoming European Society for Medical Oncology (ESMO) Congress taking place in Madrid, Spain from October 20-24, 2023. The breadth of new data showcases Bayer's ongoing commitment to supporting patients living with cancer. NUBEQA® (darolutamide) data includes further analyses from the Phase III ARASENS trial which evaluates prostate-specific antigen (PSA) outcomes of NUBEQA plus androgen depri.

Bayer Unveils Latest Data from Oncology Portfolio at ESMO Congress 2023

Dollar General

ST. LOUIS--(BUSINESS WIRE)--Bayer and Dollar General have partnered on a campaign to help K-12 school districts around the country provide nutritional support for kids and their families outside of traditional school hours. Through this partnership, students receive a coupon for fresh produce, redeemable at local Dollar General stores that now offer fresh fruit and vegetables. The collaboration was also developed to coincide with National School Lunch Week, October 9-13, which celebrates the im.

Bayer and Dollar General Partner to Increase Access to Fruit and Veggies, Celebrate National School Lunch Week

BERLIN, Germany & BERKELEY, Calif.--(BUSINESS WIRE)--Bayer AG announced today the opening of its first Cell Therapy Launch Facility in Berkeley, California to create the capacity to bring cell therapies to patients on a global scale. The $250 million (USD), 100,000-square-foot facility will supply the material required for late-stage clinical trials and potential commercial launch of BlueRock Therapeutics' bemdaneprocel (BRT-DA01), an investigational cell therapy currently in evaluation for tre.

Bayer Opens First Cell Therapy Manufacturing Facility to Advance Regenerative Medicines on a Global Scale

Ambev

Adyen NV

British American Tobacco

Anheuser-Busch InBev

Diageo

FANUC Corp

GlaxoSmithKline

Imperial Brands PLC

JD.com

Medtronic

Novozymes A/S

Omron Corp

Roche Holding AG

Safran SA

Shimano Inc

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may be worth your time for further analysis.

International Wide-Moat Stocks On Sale - The October 2023 Heat Map

Bayer (BAYRY) collaborates with Twist Bioscience to advance breakthrough innovations based on new scientific approaches and platform technologies.

Bayer (BAYRY) Partners Twist Bioscience for Drug Discovery

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Fund, a philanthropic arm of Bayer in the U.S., is excited to announce that it has provided a total of $7.4M in grant funding, spread across 1,800 extraordinary organizations, during the first half of 2023. This latest round of grants raised Bayer Fund's total giving to over $95 million since 2017 to nonprofit organizations across the U.S. Each Bayer Fund grant awarded goes toward stellar programs that are tackling some of the country's most pressing chall.

Bayer Fund Awards $7.4 Million to Nonprofit Organizations Throughout the United States in First Half of 2023

Twist Bioscience Corp

BERLIN--(BUSINESS WIRE)--Bayer AG has entered into an antibody discovery, option, and license agreement with Twist Bioscience Corporation, a company offering high-quality synthetic DNA using its silicon platform. The company's “Library of Libraries,” a collection of synthetic antibody libraries that harnesses innovative structural and developability features to cover a wide range of antibody drug targets, is tailored to address specific challenges in antibody discovery. It has the potential to.

Bayer to Partner With Twist Bioscience to Accelerate Drug Discovery

BERLIN & WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will present the latest RWE research results which focuses on treatment utilization and pathways in women with menopausal symptoms at the upcoming Menopause Society Annual Meeting (formerly The North American Menopause Society). The Menopause Society Annual Meeting takes place from September 27 – 30, in Philadelphia, Pennsylvania, USA. Key Highlights of Bayer's presentations at The Menopause Society annual meeting 2023 are: REALISE iVMS: What do w.

The Menopause Society Annual Meeting 2023: Bayer to present latest real-world evidence of menopausal symptoms and their treatment

News for Bayer AG Stock (BAYRY)